Next-Generation Sequencing and Bioinformatics-Based Protocol for the Full-Length CYP2E1 Gene Polymorphism Analysis.

ABSTRACT:

Introduction

Pharmacogenetics studies provide clinically relevant information on the identified associations between genetic variants and individual variability in drug response, which, in turn, offers great promise for guiding personalized drug therapy and clinical trial design. However, there is a lack of information concerning the evidence-based clinical annotations of specific CYP2E1 genetic variants.

Aim

To design and evaluate the next-generation sequencing-based method for full-length CYP2E1 gene polymorphism analysis.

Materials and methods

Seven gene-specific oligonucleotide primer pairs targeting overlapping CYP2E1 gene fragments spanning all nine gene exons with interleaving introns, untranslated (UTR) and intergenic regions were designed

SUBMITTER: Igumnova V 

PROVIDER: S-EPMC9653044 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature